Koss Olinger Consulting LLC Makes New $269,000 Investment in Royalty Pharma plc (NASDAQ:RPRX)

Koss Olinger Consulting LLC purchased a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,531 shares of the biopharmaceutical company's stock, valued at approximately $269,000.

Several other institutional investors also recently bought and sold shares of the business. Swedbank AB increased its stake in shares of Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after purchasing an additional 1,136,800 shares in the last quarter. State Street Corp increased its stake in Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company's stock worth $269,215,000 after buying an additional 29,451 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Royalty Pharma by 6.1% during the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock valued at $205,562,000 after acquiring an additional 417,490 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after acquiring an additional 130,025 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company's stock worth $85,809,000 after purchasing an additional 936,900 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Royalty Pharma currently has an average rating of "Buy" and an average price target of $41.60.

Royalty Pharma Trading Up 0.1 %

NASDAQ RPRX traded up $0.05 on Monday, reaching $33.75. 2,345,087 shares of the company were exchanged, compared to its average volume of 2,847,397. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business's fifty day moving average price is $32.25 and its 200 day moving average price is $28.71. The stock has a market capitalization of $19.46 billion, a P/E ratio of 23.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.61%. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.